Advertisement

L'Endocrinologo

, Volume 19, Issue 6, pp 292–296 | Cite as

Irisina: ruolo nell’omeostasi del glucosio

  • Annalisa Natalicchio
  • Nicola Marrano
  • Francesco GiorginoEmail author
Rassegna
  • 32 Downloads

Sommario

L’irisina è una miochina secreta dal muscolo scheletrico in seguito ad attività fisica, in grado di favorire il dispendio energetico grazie alla sua capacità di promuovere il browning del tessuto adiposo bianco. I livelli circolanti di irisina sono ridotti nei pazienti affetti da diabete mellito di tipo 2. Di seguito saranno riassunte le numerose evidenze sperimentali riguardanti il possibile coinvolgimento dell’irisina nell’omeostasi del glucosio e i meccanismi molecolari implicati.

Parole chiave

Irisina Insulina Glucosio Diabete 

Notes

Conflitti di interesse

Gli autori Francesco Giorgino, Annalisa Natalicchio e Nicola Marrano sono inventori di un brevetto in fase di approvazione dal titolo: “Pharmacological use of a myokine able to preserve the function and mass of the pancreatic cells under dysmetabolic conditions”. Francesco Giorgino ha ricevuto supporti da Takeda, Eli Lilly e Lifescan, ed è consulente di AstraZeneca, Eli Lilly, NovoNordisk, Roche, Sanofi e Takeda.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Supplementary material

40619_2018_498_MOESM1_ESM.doc (26 kb)
(DOC 27 kB)
40619_2018_498_MOESM2_ESM.doc (24 kb)
(DOC 24 kB)

Bibliografia

  1. 1.
    Boström P, Wu J, Jedrychowski MP et al. (2012) A PGC1-\(\alpha\)-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481:463–468 CrossRefGoogle Scholar
  2. 2.
    Perakakis N, Triantafyllou GA, Fernández-Real JM et al. (2017) Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol 13:324–337 CrossRefGoogle Scholar
  3. 3.
    Zhang Y, Li R, Meng Y et al. (2014) Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling. Diabetes 63:514–525 CrossRefGoogle Scholar
  4. 4.
    Xin C, Liu J, Zhang J et al. (2016) Irisin improves fatty acid oxidation and glucose utilization in type 2 diabetes by regulating the AMPK signaling pathway. Int J Obes (Lond) 40:443–451 CrossRefGoogle Scholar
  5. 5.
    Liu S, Du F, Li X et al. (2017) Effects and underlying mechanisms of irisin on the proliferation and apoptosis of pancreatic \(\beta\) cells. PLoS ONE 12:e0175498 CrossRefGoogle Scholar
  6. 6.
    Natalicchio A, Marrano N, Biondi G et al. (2017) The myokine irisin is released in response to saturated fatty acids and promotes pancreatic \(\beta\)-cell survival and insulin secretion. Diabetes 66:2849–2856 CrossRefGoogle Scholar
  7. 7.
    Yang M, Chen P, Jin H et al. (2014) Circulating levels of irisin in middle-aged first-degree relatives of type 2 diabetes mellitus—correlation with pancreatic \(\beta\)-cell function. Diabetol Metab Syndr 6:133 CrossRefGoogle Scholar
  8. 8.
    Huh JY, Mougios V, Kabasakalis A et al. (2014) Exercise-induced irisin secretion is independent of age or fitness level and increased irisin may directly modulate muscle metabolism through AMPK activation. J Clin Endocrinol Metab 99:2154–2161 CrossRefGoogle Scholar
  9. 9.
    Yang Z, Chen X, Chen Y et al. (2015) Decreased irisin secretion contributes to muscle insulin resistance in high-fat diet mice. Int J Clin Exp Pathol 8:6490–6497 Google Scholar
  10. 10.
    Liu T, Shi CX, Gao R et al. (2015) Irisin inhibits hepatic gluconeogenesis and increases glycogen synthesis via the PI3K/Akt pathway in type 2 diabetic mice and hepatocytes. Clin Sci (Lond) 129:839–850 CrossRefGoogle Scholar
  11. 11.
    Park MJ, Kim DI, Choi JH et al. (2015) New role of irisin in hepatocytes: the protective effect of hepatic steatosis in vitro. Cell Signal 27:1831–1839 CrossRefGoogle Scholar
  12. 12.
    So WY, Leung PS (2016) Irisin ameliorates hepatic glucose/lipid metabolism and enhances cell survival in insulin-resistant human HepG2 cells through adenosine monophosphate-activated protein kinase signaling. Int J Biochem Cell Biol 78:237–247 CrossRefGoogle Scholar
  13. 13.
    Huh JY, Dincer F, Mesfum E et al. (2014) Irisin stimulates muscle growth-related genes and regulates adipocyte differentiation and metabolism in humans. Int J Obes (Lond) 38:1538–1544 CrossRefGoogle Scholar
  14. 14.
    Xiong XQ, Chen D, Sun HJ et al. (2015) FNDC5 overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesity. Biochim Biophys Acta 1852:1867–1875 CrossRefGoogle Scholar
  15. 15.
    Emami MR, Alipoor E, Hosseinzadeh-Attar MJ (2017) Irisin—a potential contributor of insulin resistance in kidney failure. Eur J Intern Med 44:e22–e23 CrossRefGoogle Scholar
  16. 16.
    Wen MS, Wang CY, Lin SL et al. (2013) Decrease in irisin in patients with chronic kidney disease. PLoS ONE 8:e64025 CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Annalisa Natalicchio
    • 1
  • Nicola Marrano
    • 1
  • Francesco Giorgino
    • 1
    Email author
  1. 1.Dipartimento dell’Emergenza e dei Trapianti di Organi, Sezione di Medicina Interna, Endocrinologia, Andrologia e Malattie MetabolicheUniversità degli Studi di Bari Aldo MoroBariItalia

Personalised recommendations